The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will p ...

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:48 a.m. ET, incorrectly said his ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...